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ThailandPlasmodium vivax Duffy binding protein II (DBPII) plays an important role in reticulocyte invasion and is a poten-
tial vaccine candidate against vivax malaria. However, polymorphisms in DBPII are a challenge for the successful
design of a broadly protective vaccine. In this study, the genetic diversity of DBPII among Thai isolates was
analyzed from Plasmodium vivax-infected blood samples and polymorphism characters were deﬁned with the
MEGA4program. Sequence analysis identiﬁed12 variant residues that are commonamongThaiDBPII haplotypes
with variant residues L333F, L424I, W437R and I503K having the highest frequency. Variant residue D384K
occurs in combination with either E385K or K386N/Q. Additionally, variant residue L424I occurs in conjunction
withW437R inmost Thai DBPII alleles and these variants frequently occur in combinationwith the I503K variant.
The polymorphic patterns of Thai isolateswere deﬁned into 9 haplotypes (Thai DBL-1, -2, -3, etc.…). Thai DBL-2, -5,
-6 haplotypes are the most common DBPII variants in Thai residents. To study the association of these Thai DBPII
polymorphisms with antigenic character, the functional inhibition of anti-DBPII monoclonal antibodies against a
panel of Thai DBL variants was characterized by an in vitro erythrocyte binding inhibition assay. The functional
inhibition of anti-DBPII monoclonal antibodies 3C9, 2D10 and 2C6 against Thai variants was signiﬁcantly different,
suggesting that polymorphismsof ThaiDBPII variants alter the antigenic character of the target epitopes. In contrast,
anti-DBPII monoclonal antibody 2H2 inhibited all Thai DBPII variants equally well. Our results suggest that the
immune efﬁcacy of a DBPII vaccine will depend on the speciﬁcity of the anti-DBPII antibodies induced and that it
is preferable to optimize responses to conserved epitopes for broadly neutralizing protection against P. vivax.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Plasmodium vivax is a major cause of malaria worldwide leading to
N50% of the disease outside Africa, mainly afﬂicting Asia and the
Americas with approximately 2.5 billion people at risk from vivax ma-
laria [1]. The re-emergence of P. vivax in areas where it was considered
eradicated, the emergence of drug resistance, and cases of severe and
fatal vivax malaria are evidence that it persists as a signiﬁcant public
health problem. Therefore, an important part of control strategy will
be the implementation of a vaccine capable of inducing protective
immunity against P. vivax.
P. vivax Duffy binding protein (PvDBP) is a 140-kDa type 1 integral
membrane protein which belongs to a family of homologous DuffyII; DBL, Duffy binding ligand
l Microbiology and Applied
rsity, Bangkok 10700, Thailand.
land Ltd. This is an open access articlbinding-like erythrocyte binding proteins (DBL-EBP) located within
the micronemes of Plasmodium merozoites [2,3]. The critical erythro-
cyte binding motif of DBP is in a 330-amino-acid cysteine rich domain
referred to as DBP region II (DBPII) or the DBL domain. DBPII binds
Duffy antigen/receptor for chemokines (DARC) on red blood cells.
The DBP invasion ligand is considered a strong potential vaccine candi-
date against P. vivax infection in part because anti-DBP antibodies in-
hibit in vitro DBP-erythrocyte binding, reduce merozoite invasion of
human erythrocytes and confer protection against blood stage infection
[4–8]. Serological responses to DBP and the inhibitory effect of
anti-DBP antibodies against DBP-erythrocyte binding increase with a
person's age, suggesting that there is a boosting effect due to repeated
exposure through recurrent infection [4,19,7]. These data strongly
support that DBP can induce a protective immune response during
P. vivax infection.
However, PvDBPII is highly polymorphic and dbpII alleles have a very
high ratio of nonsynonymous to synonymous mutation, suggesting a
mechanism consistent with high selection pressure driving DBP allelic
diversity as a means for immune evasion [9–11]. Analysis of genetice under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
859P. Chootong et al. / Parasitology International 63 (2014) 858–864diversity of dbpII alleles among P. vivax isolates from different geograph-
ical regions, including Brazil, Colombia, South Korea and Papua New
Guinea, shows that polymorphic residues are mostly concentrated in
the ligand domain and vary by geographic region [12–14]. A study of
dbp alleles in Papua New Guinea (PNG) found that the substitution
rate within region II was 10 times greater than that found within the
dbp gene overall [9] and that 93% of DBP polymorphisms were within
the central segment of DBPII between cysteines 4 and 7 [9]. Polymorphic
residues at position 417, 437 and 503 either singly or in combination
changedDBP antigenic character,which signiﬁcantly changed sensitivity
to inhibitory antibodies directed against DBPII [15].
Analysis of ﬁeld parasites shows that some polymorphic residues
in DBPII are unique to one population or geographic region, while
some variant amino acids, K371E, D384G, E385K, K386N, N417K,
L424I, W347R and I503K are common among global vivax isolates
[12,13,16,17]. However, only a few individuals produce anti-DBP re-
sponses that broadly inhibit against multiple allelic variants [18,19].
Consequently, the polymorphic nature of PvDBPII represents a major
impediment to the successful design of a DBPII protective vaccine
against diverse P. vivax haplotypes. Better understanding of the nature
of genetic polymorphisms in DBPII of P. vivax isolates from distinct geo-
graphic areas, particularlywhere a large proportion of P. vivax infections
occur, as well as determining the correlation between DBPII polymor-
phisms and antigenic character are important for the rational design
of a broadly protective vaccine against vivax malaria. In this study we
analyzed the genetic polymorphisms of Thai DBPII variants and their
effects on antigenic character by using a set of murine monoclonal
antibodies.
2. Materials and methods
2.1. Blood samples and DNA preparation
The study was pursued in the malaria endemic areas of Southern
Thailandwhere bothmajor species ofmalaria, P. vivax and P. falciparum,
are common. The 44 blood samples used in this study were collected
from acute P. vivax-infected volunteers at malaria clinics, Chumphon
province, which is in the southern peninsular part of Thailand.
The areas are malaria endemic with high prevalence of P. vivax
infection. The conﬁrmation of P. vivax infection was performed
by microscopic examination of thin and thick Giemsa-stained
blood smears. Acute P. vivax-infected volunteers who registered
at Malarial Clinics were asked for informed consent under the
protocol approved by the Ethic Committee on Human Rights Related to
Human Experimentation, Mahidol University (MUIRB2012/162.0510).
Ten blood spots were collected on ﬁlter paper from each consenting
P. vivax patient for preparation of parasite isolates. Parasite genomic
DNA was extracted with a QIAamp DNA mini kit (Qiagen, Valencia,
CA, USA).
2.2. Gene ampliﬁcation and sequencing of PvDBPII
DBPII genes were PCR ampliﬁed by polymerase chain reaction (PCR)
using speciﬁc primers, PvDBPII F: 5′-TTTGGATCCACGATCTCTAGTGCT
ATT-3′ and PvDBPII R: 5′-AAACTCGAGTGTCACAACTTCCTGAG 3′. The
ampliﬁcation reaction was performed using the following thermal
cycling condition: 94 °C for 90 s, 30 cycles at 94 °C for 15 s, 60 °C for
35 s and 68 °C for 60 s, followed by a 68 °C extension for 2 min. HiFi
platinum Taq DNA polymerase was used in all PCR reactions. PCR prod-
ucts were analyzed on 1.2% agarose gel. PCR products were puriﬁed and
ligated into the T&A cloning vector (Invitrogen, USA). Each ligationmix-
ture was transformed into Escherichia coli DH5α competent cells and
positive clones were screened. Sequence analysis was performed on
two clones for each parasite isolate. Nucleotide sequences were obtain-
ed using the dideoxynucleotide chain termination method (Applied
Biosytems, Foster City, CA).2.3. Analysis of PvDBPII gene sequences
The alignment of complete sequences of PVDBPII genes from 44 iso-
lates was analyzed by CLUSTAL and percent similarity was assessed
using BioEdit software. Phylogenetic analysis was used to investigate
the association of PvDBPII gene with sequences from different geo-
graphic regions. The phylogenetic gene tree was constructed using
regions common to all available PvDBPII sequences. Sixty PvDBPII
gene sequences found in GenBank were compared to Thai PvDBPII
isolates including the sequence from reference strain Sal I (DQ156512),
the sequences from Vietnam (DQ156518), Indonesia (EU395591), India
(FJ491215, FJ491221 and FJ491237), Iran (EU860428 and EU860432–
438), South Korea (AAF25483, AAF25486–489 and AAZ81528), Myanmar
(JN255576–587), Sri Lanka (GU143917, GU143922, GU143936,
GU1439951, GU143953, GU143972, GU143987 and GU144012), Papua
New Guinea (AF289482, AF289635, AF289652, AF291096 and
AF469530), Brazil (EU812894, EU812906, EU812917, EU812922,
EU812927, EU812933, EU812952, EU812933, EU812942 and EU395588)
and Colombia (DQ156513, U50576, U50577, U50583, U50584 and
U50588).
2.4. pEGFP-DBPII constructs and site-directed mutagenesis
The pEGFP-DBPII construct contains the Sal I DBPII allele cloned
into the pEGFP-N1 plasmid with ﬂanking signal sequences from the
herpes simplex virus glycoprotein D1 allowing expression of a GFP
fusion protein on the surface of transiently transfected COS7 cells
[7]. Site-directed mutagenesis was used to create a panel of pEGFP-
DBPII constructs with identical polymorphisms to PvDBPII alleles
from Thai ﬁeld isolates using the pEGFP-DBPII-Sal I construct as the
parent template. Mutagenesis was performed using the Stratagene
Quickchange mutagenesis kit (Stratagene, La Jolla, CA) as previously
described [7,15,20]. The recombinant plasmid DNA was puriﬁed
using an endotoxin-free plasmid DNA puriﬁcation system (Qiagen,
Valencia, CA).
2.5. Evaluating the inhibitory efﬁciency of anti-DBPII neutralizing antibodies
against Thai PvDBPII haplotypes
We used the COS-7 cell erythrocyte assay to evaluate the ability of
previously described monoclonal antibodies to inhibit binding of
Thai DBPII and reference Sal I haplotype human erythrocytes. Our
previous study describes the production and inhibitory efﬁciency of
monoclonal antibodies 3C9, 2C6, 2D10 and 2H2 raised against
the DBL7.18 haplotype (DBL variant allele; accession number
AAL79051.1). These antibodies strongly inhibit binding of DBL7.18
to erythrocytes [29]. In this study, monoclonal antibodies 3C9, 2C6,
2D10 and 2H2were tested against Thai DBPII and reference Sal I hap-
lotypes. The construct used to express Thai DBPII or reference Sal I
haplotype on the surface of transiently transfected COS has been
used extensively as described [7]. This targeted expression efﬁciently
presents the parasite ligand on the surface of the COS cells and ex-
pression was conﬁrmed by detection of the C-terminal GFP tag using
epiﬂuorescence.
To evaluate the ability of monoclonal antibodies to inhibit bind-
ing of erythrocytes to DBP expressed on the surface of transfected
COS7 cells, various concentrations of monoclonal antibodies were
preincubated with the transfected cells for 1 h at 37 °C before addi-
tion of a 10% suspension of human erythrocytes in each well and
then incubated at room temperature for 2 h. Percent binding-
inhibition of eachmonoclonal antibodywas determined by assessing
the number of rosettes inwells of transfected COS7 cells in the presence
of monoclonal antibodies relative to rosettes in wells of transfected
cells in presence of medium control. The differences in inhibitory
efﬁciency of each monoclonal antibody to the different Thai DBPII
alleles were compared by one-way analysis of variance (ANOVA)
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done in triplicate wells and were repeated two times.
% inhibition
¼ ½1−ðnumberof rosettes inthepresenceof monoclonalantibodies
=numberof rosettes inthepresenceof mediumcontrolÞ  100:
3. Results
3.1. Genetic polymorphism of PvDBPII among Thai isolates
The analysis and comparison of amino acid sequences of Thai PvDBPII
against the reference Sal I strain (P22290.2) showed 12 polymorphic res-
idues in Thai vivax isolates (Fig. 1A). The sequence analysis classiﬁed the
mutation pattern into 9 different haplotypes (DBL-TH1, -TH2, -TH3, -TH4,
-TH5, -TH6, -TH7, -TH8 and -TH9).Most amino acid polymorphismswere
dimorphic. Only one position K386Q/N showed trimorphic polymor-
phism. All variant residues described in this study have been reported in
other P. vivax areas but the pattern of polymorphism was novel. Haplo-
type DBL-TH1was the predominant haplotype among Thai vivax isolates
(26.3%). The highest frequencies (N50%) of variant DBL-TH amino acids as
compared to the reference Sal I sequence were found at positions L333F
(78.9%), L424I (73.7%) W437R (73.4%) and I503K (63.2%) (Fig. 1B).Fig. 1. The genetic polymorphism of PvDBPII among Thai isolates. (A) Polymorphic amino a
(P22290.2). (B) Frequency of amino acid change at variant residues found in Thai DBL haplotyVariant L424I occurred in conjunction with W437R in most Thai DBPII
alleles and these variants frequently occurred in combinationwith variant
I503K. The comparison of DBL-TH haplotypes with the previously
identiﬁed PvDBPII sequences revealed that haplotypes DBL-TH2, -TH3,
-TH4, -TH5, -TH6, -TH7 and haplotype DBL-TH9 were novel in Thai
isolates. Only the DBL-TH1 haplotype was common between Thai and
Myanmar isolates.
3.2. Phylogenetic analysis of PvDBPII
Phylogenetic trees were constructed from aligned nucleotide se-
quences based on the neighbor-joining method using Tamura's three-
parameter distance (Fig. 2). The Sal I haplotype served as the reference
for each alignment and for constructing phylogenetic trees. The trees
showed that the 9 DBL-TH haplotypes were widely distributed among
different P. vivax isolates from distinct geographic regions (Fig. 2).
PvDBPII DNA sequences of Thai isolates were related to isolates from
Myanmar whereas they differed from Vietnam, Indonesia, India, South
Korea, Colombia, Iran, Sir Lanka, Brazil and PNG isolates. The Sal I refer-
ence strainwas closely related toMynmar, Iran, Brazil and Sri Lanka iso-
lates. However, the bootstrap analysis showed that Thai isolates were
distinct from the Sal I reference strain. These results indicated that
there were common DBPII haplotypes circulating in P. vivax endemic
areas of Thailand and Myanmar.cid changes are listed for each Thai DBL haplotype relative to reference sequence Sal I
pes.
861P. Chootong et al. / Parasitology International 63 (2014) 858–8643.3. Inhibitory function of anti-DBPII neutralizing antibodies against Thai
DBPII variants
To determine if there are common epitopes associated with inhibi-
tion among Thai DBPII variants, the inhibitory function of anti-DBPII
neutralizing antibodies against Thai DBPII haplotypes was assessed by
in vitro COS7 assay of Thai DBPII-erythrocyte binding. The inhibitory
efﬁciency of monoclonal antibodies 3C9, 2D10, 2C6 and 2H2 was
measured against DBPII-DBL7.18-erythrocyte binding. First, the limiting
dilution of each monoclonal antibody in the range of concentration
to get 100% to 0% inhibition activity against PvDBPII7.18-erythrocyte
binding was determined. The results showed inhibitory activity against
DBPII-DBL7.18-erythrocyte binding in a dose dependent manner
(Fig. 3). The 50% inhibitory concentrations (IC50) of 3C9, 2D10, 2C6
and 2H2 monoclonal antibodies were 0.21, 0.38, 2.61 and 0.64 μg/ml,
respectively (Fig. 3A–D).We used the IC50 of eachmonoclonal antibody
to evaluate the functional activity of anti-DBPII monoclonal antibody
against the panel of Thai DBPII variants and homologous DBL7.18
expressed in the COS7 cell assay. The results revealed little variation in
the inhibitory activity of monoclonal antibody 2H2 (Fig. 4D), suggesting
that the epitope target of this anti-DBPII neutralizing antibody was
conserved among DBL-TH variants. In contrast, there was a signiﬁcant
difference of inhibitory activity of monoclonal antibodies 3C9, 2D10
and 2C6 against the panel of Thai DBL variants (P b 0.005) (Fig. 4A–C).
The results indicate that variant epitopes among Thai isolates were
the target of most anti-DBPII neutralizing antibodies.
4. Discussion
Malaria is a major public health problem in Thailand. The surveil-
lance data show that malaria transmission is found in nearly all areas
of the country but is most prevalent along the border regions, especially
the Thai–Myanmar border. Current public health surveys indicate vivax
malaria prevalence has been on the rise in Thailand [21,22]. A signiﬁcant
portion of malaria cases in Thailand occur among temporary migrant
workers from bordering countries presenting a major challenge to pre-
vention and control of malaria in Thailand. The genetic polymorphism
in the reticulocyte binding protein (RBP), merozoite surface protein
5 (MSP-5) and merozoite surface protein 3 α/β of P. vivax Thai isolates
were analyzed in previous studies and showed high levels of genetic
polymorphism [23–26]. However, the information on the nature and
extent of population diversity as well as the antigenic character of ma-
laria parasites in Thailand is still limited. In this study, genetic polymor-
phism and its potential relationship to antigenicity of Thai PvDBPII
haplotypeswere analyzed in order to support development of a strategy
for P. vivax vaccine design in Thailand.
The 44 PvDBPII Thai isolates in this study were classiﬁed into 9
different haplotypes. Haplotype DBL-TH1 was identical to the PvDBPII
sequence in a Myanmar isolate whereas the other 8 haplotypes were
novel. A total of 12 polymorphic residues were identiﬁed which result
in signiﬁcant amino acid changes in PvDBPII Thai isolates. All variant
residues of Thai PvDBPII have been previously reported in global vivax
isolates [12,13,17,27]. The most prevalent polymorphic variants in
Thai PvDBPII variants were L333F (78.9%), L424I (73.7%), W437R
(73.4%) and I503K (63.2%) variants. Analysis of the L424I, W437R and
I503K variants showed that the L424I–W437R, L424I–I503K and
L424I–W437R–I503K combinations occurred with high frequencies of
73.7%, 57.9% and 57.2%, respectively. A previous study demonstrated
that the W437R variant combined with the N417K or I503K variant
can alter DBP antigenic character and can affect the efﬁciency of in-
hibitory antibodies against DBPII-erythrocyte binding [15]. Therefore,Fig. 2. Phylogenetic analysis. The phylogenetic tree of the 9 Thai DBPII haplotypes was
constructed with a neighbor-joining method using MEGA4 program. Numbers of the
branches indicate bootstrap proportion (1000 replicates). The novel Thailand DBPII
haplotypes are marked with asterisks.
Fig. 3. Determination of 50% inhibitory concentration (IC50) of anti-DBPII monoclonal antibodies. Monoclonal antibodies 3C9, 2D10, 2C6 and 2H2 speciﬁc to PvDBPII 7.18 were tested for
their inhibitory function against the homologous PvDBPII 7.18 haplotype. The transfected COS7 cells expressing PvDBPII 7.18 allelewere incubatedwithmonoclonal antibodies at different
concentrations and with human erythrocytes. The number of rosettes was compared between wells of transfected cells incubated with monoclonal antibodies relative to wells without
antibodies. Curves represent mean percent inhibition of two experiments tested in triplicate. Dotted line shows point on curve where IC50 of each antibody is achieved.
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antigenicity and thus, the anti-DBPII response. Additional studies of
naturally-acquired immunity against Thai DBPII protein antigens will
be important for effective vaccine design.
Phylogenetic analysis revealed that Thai DBPII isolates had broad
genetic diversity. A total of 9 Thai PvDBPII haplotypes were distributed
among other geographic regions: Brazil, Papua New Guinea, Myanmar,
Vietnam, Indonesia, Iran, Colombia, Sri Lanka, South Korea and India.
The PvDBPII phylogeny showed that Thai PvDBPII isolates shared a
common ancestor close to Myanmar isolates. The highest prevalence
of L333F, L424I, W437R and I503K variants was common in Thai and
Myanmar isolates [12]. However, there are 11 polymorphisms (I310L,
F344S, R391H, K455I, K473R, C477G, R490K, D528G, V533M, K541T
and A545V) found only in Myanmar isolates and not present in Thai
isolates [12]. Taken together, these results indicate that immigration
and/or travel are likely to inﬂuence the frequency of PvDBPII haplotypes
between Thailand and Myanmar.
A signiﬁcant challenge for DBPII vaccine development is its high
level of polymorphism and the resulting strain-speciﬁc immunity.
Previous studies have shown that individuals exposed to P. vivax para-
sites develop naturally acquired immunity [5,18,19]. However, most in-
dividuals develop strain speciﬁc immunity, with only a few individuals
capable of producing broadly neutralizing anti-DBPII antibodies [28].
Vaccine design needs to identify neutralizing antibodies against con-
served epitopes while avoiding presentation of immunogenic variant
epitopes in a potential DBPII vaccine. Our objective was to evaluatethe activity of broadly inhibitory anti-DBPII monoclonal antibodies
against the diverse Thai DBPII variants identiﬁed in this study.
We analyzed the ability of anti-PvDBPII antibodies to inhibit
Thai PvDBPII variant–erythrocyte binding by using an in vitro COS-7
erythrocyte-binding-inhibition assay. The concentration of monoclonal
antibodies to achieve 50% inhibition against the homologous strain
(IC50) was used to compare the inhibition efﬁciency against Thai
PvDBPII variants. Monoclonal antibody 3C9 (IC50 = 0.21) had the
strongest inhibition activity against homologous DBP7.18, followed by
2D10 (IC50= 0.38), 2H2 (IC50= 0.64) and 2C6 (IC50= 2.61), respec-
tively. A signiﬁcant difference in inhibitory function against heterolo-
gous Thai variants was found in the 3C9, 2D10 and 2C6 monoclonal
antibodies (Fig. 4A–C, P b 0.005), indicating that the these monoclonal
antibodies may bind to different epitopes of Thai DBPII variants. Im-
mune activity of 3C9, 2D10 and 2C6 monoclonal antibodies showed a
trend toward variant-speciﬁc antibody with the individual Thai DBPII
alleles. These results strongly support that the genetic polymorphisms
of PvDBPII can alter antigenic character and thus may confer signiﬁcant
changes in their sensitivity to inhibitory function of anti-DBPII neutral-
izing antibodies as previously reported [8,15,19,28].
Immunization with PvDBP7.18 antigen showed a higher inhibitory
response against Thai DBPII variants than against the homologous
7.18 haplotype. This data is supported by our observation that Mab
2C6 showed stronger inhibitory activity against DBPII-Sal I than against
homologous DBPII7.18 (2C6; IC50 = 1.01 μg/ml in DBPII Sal I, IC50 =
2.61 μg/ml in DBPII7.18, data not shown). Our data is also in line with
Fig. 4. Functional inhibition of anti-DBPII monoclonal antibodies against the panel of DBL-TH variants. The transfected COS7 cell expressing DBPII reference Sal I or 7.18 or DBL-TH variants
were pre-incubatedwithmonoclonal antibodies at concentrations set to the IC50 of the DBP7.18 haplotype antigen for inhibition of DBPII-erythrocyte binding. The charts show themean
inhibition of each DBL-TH variant. The variation in means across DBL-TH variants shows signiﬁcant differences in the inhibitory responses of 3C9, 2D10 and 2C6 monoclonal antibodies.
COS7 experiments for each monoclonal antibody were done in triplicate wells of each DBL variant and were repeated two times. Statistical signiﬁcance was determined using one-way
analysis of variance (ANOVA).
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DBPII enhanced sensitivity to heterologous anti-DBPII antibody while
other amino acid changes in the same residues increased refractoriness
to antibody inhibition [15].
Interestingly, a number of DBPII neutralizing epitopes are shared
among Thai DBPII variants. We have shown that a conserved epitope
shared among Thai PvDBPII variants appears to be the target of the
2H2 anti-DBPII neutralizing monoclonal antibody (Fig. 4D). This data
strongly supports that DBPII immunity has the potential to generate
neutralizing antibodies against a range of variant haplotypes for broader
strain recognition. The development of a broadly protective anti-DBPII
vaccine to the dominant DBPII variants in ﬁeld parasites will require
induction of antibodies targeting epitopes that are conserved among
variant DBPII alleles, such as those recognized by the 2H2 monoclonal
antibody indicated in this study.Acknowledgments
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